Comparative study of neoadjuvant chemotherapy before radical hysterectomy and radical surgery alone in stage IB2-IIA bulky cervical cancer.
- Author:
Yun Hyun CHO
1
;
Dae Yeon KIM
;
Jong Hyeok KIM
;
Yong Man KIM
;
Young Tak KIM
;
Joo Hyun NAM
Author Information
- Publication Type:Comparative Study ; Original Article
- Keywords: Locally advanced cervical cancer; Neoadjuvant chemotherapy; Radical hysterectomy
- MeSH: Humans; Hysterectomy; Lymph Nodes; Neoplasm Metastasis; Paclitaxel; Platinum; Prognosis; Quality of Life; Radiotherapy, Adjuvant; Recurrence; Risk Factors; Uterine Cervical Neoplasms
- From:Journal of Gynecologic Oncology 2009;20(1):22-27
- CountryRepublic of Korea
- Language:English
- Abstract: OBJECTIVE: To compare the efficacy of neoadjuvant chemotherapy with paclitaxel plus platinum followed by radical hysterectomy with radical surgery alone in patients with stage IB2-IIA bulky cervical cancer. METHODS: From November 1999 to September 2007, stage IB2-IIA cervical cancers with tumor diameter >4 cm, as measured by MRI, were managed with two cycles of preoperative paclitaxel and platinum. As a control group, we selected 35 patients treated with radical surgery alone. RESULTS: There were no significant between group differences in age, tumor size, FIGO stage, level of SCC Ag, histopathologic type and grade. Operating time, estimated blood loss, the number of lymph nodes yielded and the rate of complications were similar in the two groups. In surgical specimens, lymph-vascular space invasion (LVSI), nodal metastasis and parametrial involvement did not differ significantly between the two groups. In the neoadjuvant group, pathologic tumor size was significantly smaller and fewer patients had deep cervical invasion. Radiotherapy, alone and in the form of concurrent chemoradiation, was administered to more patients treated with radical surgery alone (82.9% vs. 52.9%, p=0.006). No recurrence was observed in patients who could avoid adjuvant radiotherapy owing to improved risk factors after neoadjuvant chemotherapy. There were no significant differences in 5-year disease free and overall survival. CONCLUSION: As neoadjuvant chemotherapy would improve pathologic prognostic factors, adjuvant radiotherapy can be avoided, without worsening the prognosis, in patients with locally advanced bulky cervical cancer. Neoadjuvant chemotherapy would be improving the quality of life after radical hysterectomy in patients with bulky cervical cancer.
